Helen E. Rich

Helen E. Rich

Auto-generated profile, based on publicly available information

Helen E. Rich

Cerberus Therapeutics

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2019 in Clinical Microbiology Reviews
Verified
Journal Article
Closed access
PDF file
JGJennifer A. Grousd
Jennifer A. Grousd
HRHelen E. Rich
Helen E. Rich
JAJohn Alcorn
John Alcorn
Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality worldwide. Despite broad literature including basic and translational scientific studies, many gaps in our understanding of host-pathogen interactions remain.

25 September 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
RGRadha Gopal
Radha Gopal
Benjamin LeeBenjamin Lee
Benjamin Lee
KMKevin J. McHugh
Kevin J. McHugh
HRHelen E. Rich
Helen E. Rich
KRKrishnaveni Ramanan
Krishnaveni Ramanan
JAJohn Alcorn
John Alcorn
Influenza is a common respiratory virus that infects between 5-20% of the US population and results in 30,000 deaths annually. A primary cause of influenza-associated death is secondary bacterial pneumonia. We have previously shown that influenza induces type I interferon (IFN)-mediated inhibition of Type 17 immune responses, resulting in exacerbation of bacterial burden during influenza and Staphylococcus aureus super-infection. In this study, we investigated the role of STAT2 signaling during influenza and influenza-bacterial super-infection in mice. Influenza-infected STAT2-/- mice had increased morbidity, viral burden, and inflammation when compared to wild-type mice. Despite an exaggerated inflammatory response to influenza infection, we found increased bacterial control and survival in STAT2 deficient mice during influenza-MRSA super-infection compared to controls. Further, we found that increased bacterial clearance during influenza-MRSA super-infection is not due to rescue of Type 17 immunity. Absence of STAT2 was associated with increased accumulation of M1, M2 and M1/M2 co-expressing macrophages during influenza-bacterial super-infection. Neutralization of IFNγ (M1) and/or Arginase 1 (M2) impaired bacterial clearance in Stat2-/- mice during super-infection, demonstrating that pulmonary macrophages expressing a mixed M1/M2 phenotype promote bacterial control during influenza-bacterial super-infection. Together, these results suggest that the STAT2 signaling is involved in suppressing macrophage activation and bacterial control during influenza-bacterial super-infection. Further, these studies reveal novel mechanistic insight into the roles of macrophage subpopulations in pulmonary host defense.

1 May 2019 in Infection and Immunity
Verified
Journal Article
Closed access
PDF file
HRHelen E. Rich
Helen E. Rich
CMCollin C. McCourt
Collin C. McCourt
WZWen Quan Zheng
Wen Quan Zheng
KMKevin J. McHugh
Kevin J. McHugh
KRKeven M. Robinson
Keven M. Robinson
JAJohn Alcorn
John Alcorn
Influenza kills 30-40,000 people each year in the United States, and causes ten times as many hospitalizations. A common complication of influenza is bacterial super-infection, which exacerbates morbidity and mortality from the viral illness. Recently, MRSA has emerged as the dominant pathogen found in bacterial super-infection, with Streptococcus pneumoniae a close second. However, clinicians have few tools to treat bacterial super-infection. Current therapy for influenza/bacterial super-infection consists of treating the underlying influenza infection, adding various antibiotics which are increasingly rendered ineffective by rising bacterial multi-drug resistance. Several groups have recently proposed using the antiviral cytokine interferon lambda (IFN-λ) as a therapeutic for influenza, as administration of pegylated IFN-λ improves lung function and survival during influenza by reducing the overabundance of neutrophils in the lung. However, our data suggest that therapeutic IFN-λ impairs bacterial clearance during influenza super-infection. Specifically, mice treated with an adenoviral vector to overexpress IFN-λ during influenza infection exhibited increased bacterial burden upon super-infection with either MRSA or S. pneumoniae. Surprisingly, adhesion molecule expression, antimicrobial peptide production, and reactive oxygen species activity were not altered by IFN-λ treatment. However, neutrophil uptake of MRSA and S. pneumoniae was significantly reduced upon IFN-λ treatment during influenza super-infection in vivo. Together, these data support the theory that IFN-λ decreases neutrophil motility and function in the influenza-infected lung, which increases bacterial burden during super-infection. Thus, we believe caution should be exercised in the possible future use of IFN-λ as therapy for influenza.

12 April 2017 in Mucosal Immunology
Verified
Journal Article
Open access
PDF file
KRK M Robinson
K M Robinson
KRK Ramanan
K Ramanan
MCM E Clay
M E Clay
KMK J McHugh
K J McHugh
HRH E Rich
H E Rich
JAJohn Alcorn
John Alcorn
Influenza A is a highly contagious respiratory virus that causes seasonal epidemics and occasional worldwide pandemics. The primary cause of influenza-related mortality is bacterial superinfection. There are numerous mechanisms by which preceding influenza infection attenuates host defense, allowing for increased susceptibility to bacterial pneumonia. Herein, we demonstrate that influenza inhibits Staphylococcus aureus-induced production of interleukin-33 (IL-33). Restoration of IL-33 during influenza A and methicillin-resistant S. aureus superinfection enhanced bacterial clearance and improved mortality. Innate lymphoid Type 2 cells and alternatively activated macrophages are not required for IL-33-mediated protection during superinfection. We show that IL-33 treatment resulted in neutrophil recruitment to the lung, associated with improved bacterial clearance. These findings identify a novel role for IL-33 in antibacterial host defense at the mucosal barrier.

1 June 2019 in Viruses
Verified
Journal Article
Open access
PDF file
RGRadha Gopal
Radha Gopal
AMAngelico Mendy
Angelico Mendy
MMMichael A. Marinelli
Michael A. Marinelli
LRLacee J. Richwalls
Lacee J. Richwalls
PSPhilip J. Seger
Philip J. Seger
JAJohn Alcorn
John Alcorn
Influenza virus is among the most common causes of respiratory illness worldwide and can be complicated by secondary bacterial pneumonia, a frequent cause of mortality. When influenza virus infects the lung, the innate immune response is activated, and interferons and inflammatory mediators are released. This “cytokine storm” is thought to play a role in influenza-induced lung pathogenesis. Peroxisome proliferator-activated receptor gamma (PPARγ) is a member of the nuclear hormone receptor super-family. PPARγ has numerous functions including enhancing lipid and glucose metabolism and cellular differentiation and suppressing inflammation. Synthetic PPARγ agonists (thiazolidinediones or glitazones) have been used clinically in the treatment of type II diabetes. Using data from the National Health and Nutrition Examination Survey (NHANES), diabetic participants taking rosiglitazone had an increased risk of mortality from influenza/pneumonia compared to those not taking the drug. We examined the effect of rosiglitazone treatment during influenza and secondary bacterial (Methicillin resistant Staphylococcus aureus) pneumonia in mice. We found decreased influenza viral burden, decreased numbers of neutrophils and macrophages in bronchoalveolar lavage, and decreased production of cytokines and chemokines in influenza infected, rosiglitazone-treated mice when compared to controls. However, rosiglitazone treatment compromised bacterial clearance during influenza-bacterial super-infection. Both human and mouse data suggest that rosiglitazone treatment worsens the outcome of influenza-associated pneumonia.

3 November 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
THThibault J. Harmand
Thibault J. Harmand
LPLaura Pietrok
Laura Pietrok
HRHelen Rich
Helen Rich
RDRhogerry Deshycka
Rhogerry Deshycka
LFLaney Flanagan
Laney Flanagan
HPHidde L. Ploegh
Hidde L. Ploegh
We describe the production and use of nanobody drug conjugates that comprise of VHH kappa , a nanobody that recognizes mouse immunoglobulin kappa light chains, and one or more copies of the small molecule influenza virus neuraminidase (NA) inhibitor, zanamivir. Such compounds achieve half-life extension of zanamivir, while recruiting polyclonal immunoglobulins of all isotypes regardless of specificity to infected cells for antibody-dependent cell-mediated cytotoxicity and complement-dependent cellular cytotoxicity. Since the influenza A virus (IAV) NA is a tetramer, we produced VHH kappa adducts with 1, 2, or 4 zanamivir molecules attached in a site-specific manner, to allow multivalent engagement of NA. Administration of a VHH kappa adduct modified with 4 zanamivir molecules (VHH kappa –Zan 4 ) was ~10-fold more potent in protection against infection with IAV than VHH kappa –Zan carrying only a single zanamivir molecule. VHH kappa –Zan 4 can be given intranasally to confer full protection against a lethal IAV challenge. The neutralizing antibody titers in the respiratory mucosa and in the circulation, as well as the serum IgG antibody response against the hemagglutinin and nucleoprotein, are higher in VHH kappa –Zan 4 treated mice that survived the lethal challenge than in controls infected with a sublethal dose of virus. VHH kappa –Zan 4 affords protection even when given intranasally weeks prior to a challenge with a lethal dose of IAV. This type of adduct can therefore be applied prophylactically and therapeutically and does not require prior immunization for protection against a lethal dose of IAV.